New scalp treatment for chemo hair loss under early safety review
NCT ID NCT07402330
First seen Feb 22, 2026 · Last updated May 22, 2026 · Updated 9 times
Summary
This early-phase study looks at how much of the drug DA-020 gets into the blood after a single application to the scalp. It involves 60 healthy women aged 18-55. The goal is to measure drug levels and check for side effects like blood pressure changes. This is a first step before testing in people with chemotherapy-related hair loss.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHEMOTHERAPY INDUCED ALOPECIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Hospital Samel
Manaus, Brazil
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Rome ("G. Marconi")
Rome, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.